La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Ajanta Pharma Résultats passés
Passé contrôle des critères 6/6
Ajanta Pharma a connu une croissance annuelle moyenne de ses bénéfices de 11%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 15.2% par an. Les revenus ont augmenté de en hausse à un taux moyen de 12.9% par an. Le rendement des capitaux propres de Ajanta Pharma est 23.9% et ses marges nettes sont de 19.7%.
Informations clés
11.0%
Taux de croissance des bénéfices
11.9%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 17.5% |
Taux de croissance des recettes | 12.9% |
Rendement des fonds propres | 23.9% |
Marge nette | 19.7% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25You Have To Love Ajanta Pharma Limited's (NSE:AJANTPHARM) Dividend
Dec 13Is Ajanta Pharma Limited's (NSE:AJANTPHARM) Recent Stock Performance Influenced By Its Financials In Any Way?
Dec 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Is Interesting
Nov 19Ventilation des recettes et des dépenses
Comment Ajanta Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 43,326 | 8,538 | 9,828 | 0 |
31 Mar 24 | 42,087 | 8,162 | 9,122 | 0 |
31 Dec 23 | 40,365 | 7,357 | 9,031 | 0 |
30 Sep 23 | 39,031 | 6,602 | 8,642 | 0 |
30 Jun 23 | 38,128 | 6,215 | 8,280 | 0 |
31 Mar 23 | 37,426 | 5,880 | 7,978 | 0 |
31 Dec 22 | 37,311 | 6,169 | 7,383 | 0 |
30 Sep 22 | 35,972 | 6,742 | 7,081 | 0 |
30 Jun 22 | 35,439 | 7,136 | 6,821 | 0 |
31 Mar 22 | 33,410 | 7,127 | 6,571 | 0 |
31 Dec 21 | 32,275 | 7,207 | 6,301 | 0 |
30 Sep 21 | 31,384 | 7,056 | 6,041 | 0 |
30 Jun 21 | 29,695 | 6,799 | 5,745 | 0 |
31 Mar 21 | 28,897 | 6,539 | 5,523 | 0 |
31 Dec 20 | 28,148 | 6,238 | 5,354 | 0 |
30 Sep 20 | 27,173 | 5,547 | 5,196 | 0 |
30 Jun 20 | 26,441 | 5,008 | 5,065 | 0 |
31 Mar 20 | 25,879 | 4,677 | 4,890 | 0 |
31 Dec 19 | 24,211 | 4,274 | 4,831 | 0 |
30 Sep 19 | 22,550 | 3,868 | 4,755 | 0 |
30 Jun 19 | 21,563 | 3,958 | 4,639 | 0 |
31 Mar 19 | 20,554 | 3,870 | 4,503 | 0 |
31 Dec 18 | 20,654 | 3,926 | 4,428 | 0 |
30 Sep 18 | 21,674 | 4,731 | 4,252 | 0 |
30 Jun 18 | 21,636 | 4,796 | 4,089 | 0 |
31 Mar 18 | 21,258 | 4,686 | 3,908 | 0 |
31 Dec 17 | 20,590 | 4,882 | 3,574 | 0 |
30 Sep 17 | 20,050 | 4,833 | 3,397 | 0 |
30 Jun 17 | 19,805 | 4,821 | 3,224 | 0 |
31 Mar 17 | 19,833 | 5,068 | 3,060 | 0 |
31 Dec 16 | 19,386 | 4,908 | 3,097 | 0 |
30 Sep 16 | 18,821 | 4,622 | 2,971 | 0 |
30 Jun 16 | 18,072 | 4,350 | 2,886 | 0 |
31 Mar 16 | 17,340 | 4,156 | 2,773 | 0 |
31 Dec 15 | 16,809 | 3,692 | 5,446 | 0 |
30 Sep 15 | 16,160 | 3,510 | 5,318 | 0 |
30 Jun 15 | 15,502 | 3,340 | 5,158 | 0 |
31 Mar 15 | 14,736 | 3,099 | 2,167 | 0 |
31 Mar 14 | 12,083 | 2,339 | 4,096 | 0 |
Des revenus de qualité: AJANTPHARM a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de AJANTPHARM (19.7%) sont supérieures à celles de l'année dernière (16.3%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de AJANTPHARM ont augmenté de 11% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de AJANTPHARM au cours de l'année écoulée ( 37.4% ) dépasse sa moyenne sur 5 ans ( 11% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices AJANTPHARM au cours de l'année écoulée ( 37.4% ) a dépassé celle du secteur Pharmaceuticals 19.3%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de AJANTPHARM ( 23.9% ) est considéré comme élevé.